Q3 2021 13F Holders as of 30 Sep 2021
-
Type / Class
-
Equity / Common Stock, $0.01 par value
-
Shares outstanding
-
82,051,282
-
Number of holders
-
38
-
Total 13F shares, excl. options
-
13,600,109
-
Shares change
-
+7,596,653
-
Total reported value, excl. options
-
$223,717,000
-
Value change
-
+$123,512,129
-
Number of buys
-
32
-
Number of sells
-
-6
-
Price
-
$16.45
Significant Holders of Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value (VRDN) as of Q3 2021
45 filings reported holding VRDN - Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value as of Q3 2021.
Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value (VRDN) has 38 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 13,600,109 shares
of 82,051,282 outstanding shares and own 16.6% of the company stock.
Largest 10 shareholders include FRAZIER MANAGEMENT LLC (1,505,200 shares), Logos Global Management LP (1,500,000 shares), PERCEPTIVE ADVISORS LLC (1,423,000 shares), Vivo Capital, LLC (1,300,000 shares), Fairmount Funds Management LLC (944,092 shares), Ally Bridge Group (NY) LLC (904,978 shares), BVF INC/IL (804,126 shares), D. E. Shaw & Co., Inc. (720,530 shares), COMMODORE CAPITAL LP (667,674 shares), and Point72 Asset Management, L.P. (610,000 shares).
This table shows the top 38 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.